The Effect of Cilostazol on Endothelial Function As Assessed by Flow-Mediated Dilation in Patients with Coronary Artery Disease

Overview

Journal J Atheroscler Thromb

Date 2016 May 13

PMID 27169919

Citations 7

Authors

Hiroyoshi Mori

Atsuo Maeda

Kohei Wakabayashi

Tokutada Sato

Masahiro Sasai

Kazuma Tashiro

Yoshitaka Iso

Mio Ebato

Hiroshi Suzuki

Affiliations

Soon will be listed here.

Abstract

Aim: The vascular endothelium plays a key role in the pathophysiology of atherosclerosis. Flow-mediated dilation (FMD) is a novel way of assessing endothelial function. Cilostazol is a unique antiplatelet drug that also has the potential to improve endothelial function. The objective of this present study was to investigate the effects of cilosatzol on endothelial function as assessed by FMD.

Methods: Fifty-one patients with coronary artery disease (CAD) were assigned to one of two groups: the Cilostazol(+) group (with cilostazol) and Cilostazol(-) group (without cilostazol). In addition to conventional dual antiplatelet therapy with aspirin and clopidogrel/ticlopidine, the Cilostazol(+) group (n=27) was also given cilostazol (100 mg/day). The Cilostazol(-) group (n=24) did not receive cilostazol. FMD was assessed at enrollment and after 6-9 months.

Results: The FMD of both the Cilostazol(+) and Cilostazol(-) groups remained similar at 5.2 (interquartile range: 3.8-8.5) to 5.4 (interquartile range: 4.2-6.7) (P=0.29) and 5.0 (interquartile range: 3.6-6.4) to 4.9 (interquartile range: 4.0-7.0) (P=0.38), respectively. However, the diameters of the baseline and maximal brachial arteries tended to increase in the Cilostazol(+) group (baseline: 4.2±0.7 to 4.4±0.7, P=0.18; maximal: 4.5±0.7 to 4.6±0.7 P=0.22), whereas that of the Cilostazol(-) group tended to decrease (baseline: 4.1±0.6 to 3.9±0.5, P=0.10; maximal: 4.3±0.7 to 4.1±0.5, P=0.05). The rates of change in the baseline diameter (Cilostazol(+): 3.7±9.8% vs. Cilostazol(-): -3.8±12.2%, P=0.03) and maximal diameter (Cilostazol(+): +3.1±8.9% vs. Cilostazol(-): -4.4±12.0%, P=0.02) were significantly different.

Conclusion: Although cilostazol didn't affect the FMD, there was a significant difference in the rates of change in baseline and maximal brachial artery diameter. This may have a beneficial effect in patients with cardiovascular disease.

Citing Articles

Cell-free plasma telomere length correlated with the risk of cardiovascular events using machine learning classifiers.

Dai M, Li K, Sacirovic M, Zemmrich C, Ritter O, Bramlage P Sci Rep. 2024; 14(1):30390.

PMID: 39639031 PMC: 11621410. DOI: 10.1038/s41598-024-76686-2.

A Comprehensive Review of Clinical Studies Applying Flow-Mediated Dilation.

Ahn Y, Aung N, Ahn H Diagnostics (Basel). 2024; 14(22).

PMID: 39594169 PMC: 11592698. DOI: 10.3390/diagnostics14222499.

Alpha-2-macroglobulin as a Promising Biological Marker of Endothelial Function.

Shimomura R, Nezu T, Hosomi N, Aoki S, Sugimoto T, Kinoshita N J Atheroscler Thromb. 2017; 25(4):350-358.

PMID: 29093276 PMC: 5906188. DOI: 10.5551/jat.41335.

Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique.

Lee S, Lee J, Choi M, Lee S, Shin D, Hong J BMC Neurol. 2017; 17(1):169.

PMID: 28851320 PMC: 5576326. DOI: 10.1186/s12883-017-0950-y.

Flow Mediated Dilatation as a Biomarker in Vascular Surgery Research.

Bellamkonda K, Williams M, Ashok Handa , Lee R J Atheroscler Thromb. 2017; 24(8):779-787.

PMID: 28674324 PMC: 5556184. DOI: 10.5551/jat.40964.

References

Poredos P, Jezovnik M . Testing endothelial function and its clinical relevance. J Atheroscler Thromb. 2012; 20(1):1-8. DOI: 10.5551/jat.14340. View

Celermajer D, Sorensen K, Gooch V, Spiegelhalter D, Miller O, Sullivan I . Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 340(8828):1111-5. DOI: 10.1016/0140-6736(92)93147-f. View

Lee S, Park S, Kim Y, Yun S, Park D, Lee C . Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting.... J Am Coll Cardiol. 2008; 51(12):1181-7. DOI: 10.1016/j.jacc.2007.11.049. View

Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T . Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001; 104(22):2673-8. DOI: 10.1161/hc4601.099485. View

. Guidelines for elective percutaneous coronary intervention in patients with stable coronary artery disease (JCS 2011) published in 2012--digest version. Circ J. 2013; 77(6):1590-607. DOI: 10.1253/circj.cj-66-0065. View

Oida K, Ebata K, Kanehara H, Suzuki J, Miyamori I . Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers. J Atheroscler Thromb. 2003; 10(2):93-8. DOI: 10.5551/jat.10.93. View

Jeong I, Park J, Jin S, Kim J, Lee J, Choi S . Oral sarpogrelate can improve endothelial dysfunction as effectively as oral cilostazol, with fewer headaches, in active young male smokers. Heart Vessels. 2012; 28(5):578-82. DOI: 10.1007/s00380-012-0282-1. View

. Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011). Circ J. 2012; 77(1):231-48. DOI: 10.1253/circj.cj-66-0053. View

Goto S . Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005; 6(4):3-11. DOI: 10.1016/j.atherosclerosissup.2005.09.002. View

10.

Packer M, Carver J, Rodeheffer R, Ivanhoe R, DiBianco R, Zeldis S . Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991; 325(21):1468-75. DOI: 10.1056/NEJM199111213252103. View

11.

Lee S, Chun K, Park S, Kim H, Kim Y, Yun S . Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials). Am J Cardiol. 2010; 105(2):168-73. DOI: 10.1016/j.amjcard.2009.08.667. View

12.

Atkinson G, Batterham A . The clinical relevance of the percentage flow-mediated dilation index. Curr Hypertens Rep. 2015; 17(2):4. DOI: 10.1007/s11906-014-0514-0. View

13.

Chen K, Rha S, Li Y, Poddar K, Jin Z, Minami Y . Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation. 2009; 119(25):3207-14. DOI: 10.1161/CIRCULATIONAHA.108.822791. View

14.

Iida O, Yokoi H, Soga Y, Inoue N, Suzuki K, Yokoi Y . Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation. 2013; 127(23):2307-15. DOI: 10.1161/CIRCULATIONAHA.112.000711. View

15.

Lind L . Flow-mediated vasodilation was found to be an independent predictor of changes in the carotid plaque status during a 5-year follow-up. J Atheroscler Thromb. 2013; 21(2):161-8. DOI: 10.5551/jat.18572. View

16.

Levine G, Keaney Jr J, Vita J . Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med. 1995; 332(8):512-21. DOI: 10.1056/NEJM199502233320807. View

17.

Cohn J, Goldstein S, GREENBERG B, Lorell B, Bourge R, Jaski B . A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998; 339(25):1810-6. DOI: 10.1056/NEJM199812173392503. View

18.

Rajagopalan S, Pfenninger D, Somers E, Kehrer C, Chakrabarti A, Mukherjee D . Effects of cilostazol in patients with Raynaud's syndrome. Am J Cardiol. 2003; 92(11):1310-5. DOI: 10.1016/j.amjcard.2003.08.013. View

19.

Suh J, Lee S, Park K, Lee H, Kang H, Koo B . Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy.... J Am Coll Cardiol. 2011; 57(3):280-9. DOI: 10.1016/j.jacc.2010.08.631. View

20.

Takase B, Nagata M, Hattori H, Tanaka Y, Ishihara M . Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study. Med Princ Pract. 2013; 23(1):59-65. PMC: 5586847. DOI: 10.1159/000355825. View